Surmodics Valuation

Is SRDX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SRDX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SRDX ($33.33) is trading below our estimate of fair value ($73.93)

Significantly Below Fair Value: SRDX is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SRDX?

Other financial metrics that can be useful for relative valuation.

SRDX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.5x
Enterprise Value/EBITDA13x
PEG Ratio1.2x

Price to Earnings Ratio vs Peers

How does SRDX's PE Ratio compare to its peers?

The above table shows the PE ratio for SRDX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.9x
TCMD Tactile Systems Technology
11.9x6.7%US$327.2m
ZYXI Zynex
45.8x36.6%US$348.6m
VREX Varex Imaging
15.1x10.7%US$660.1m
IRMD IRADIMED
30.9x9.8%US$514.3m
SRDX Surmodics
35.1x30.5%US$365.7m

Price-To-Earnings vs Peers: SRDX is expensive based on its Price-To-Earnings Ratio (35.1x) compared to the peer average (25.9x).


Price to Earnings Ratio vs Industry

How does SRDX's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.2%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.2%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: SRDX is good value based on its Price-To-Earnings Ratio (35.1x) compared to the US Medical Equipment industry average (36x).


Price to Earnings Ratio vs Fair Ratio

What is SRDX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SRDX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio35.1x
Fair PE Ratio34.5x

Price-To-Earnings vs Fair Ratio: SRDX is expensive based on its Price-To-Earnings Ratio (35.1x) compared to the estimated Fair Price-To-Earnings Ratio (34.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SRDX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$33.33
US$58.00
+74.0%
25.2%US$75.00US$43.00n/a4
Apr ’25US$27.90
US$59.00
+111.5%
23.1%US$75.00US$44.00n/a4
Mar ’25US$32.07
US$59.00
+84.0%
23.1%US$75.00US$44.00n/a4
Feb ’25US$32.43
US$59.25
+82.7%
23.4%US$75.00US$44.00n/a4
Jan ’25US$36.35
US$58.50
+60.9%
24.9%US$75.00US$44.00n/a4
Dec ’24US$33.39
US$58.50
+75.2%
24.9%US$75.00US$44.00n/a4
Nov ’24US$29.78
US$59.50
+99.8%
21.6%US$75.00US$44.00n/a4
Oct ’24US$32.09
US$59.50
+85.4%
21.6%US$75.00US$44.00n/a4
Sep ’24US$36.20
US$59.50
+64.4%
21.6%US$75.00US$44.00n/a4
Aug ’24US$31.18
US$54.75
+75.6%
31.8%US$75.00US$36.00n/a4
Jul ’24US$31.31
US$54.75
+74.9%
31.8%US$75.00US$36.00n/a4
Jun ’24US$18.23
US$56.33
+209.0%
30.1%US$75.00US$34.00n/a3
May ’24US$22.99
US$56.33
+145.0%
30.1%US$75.00US$34.00US$33.333
Apr ’24US$22.78
US$56.33
+147.3%
30.1%US$75.00US$34.00US$27.903
Mar ’24US$21.93
US$56.33
+156.9%
30.1%US$75.00US$34.00US$32.073
Feb ’24US$28.47
US$54.00
+89.7%
28.6%US$75.00US$34.00US$32.434
Jan ’24US$34.12
US$70.75
+107.4%
37.4%US$114.00US$46.00US$36.354
Dec ’23US$35.93
US$70.75
+96.9%
37.4%US$114.00US$46.00US$33.394
Nov ’23US$33.98
US$74.00
+117.8%
33.5%US$114.00US$46.00US$29.784
Oct ’23US$30.40
US$74.00
+143.4%
33.5%US$114.00US$46.00US$32.094
Sep ’23US$32.86
US$74.00
+125.2%
33.5%US$114.00US$46.00US$36.204
Aug ’23US$34.76
US$74.00
+112.9%
33.5%US$114.00US$46.00US$31.184
Jul ’23US$37.82
US$74.00
+95.7%
33.5%US$114.00US$46.00US$31.314
Jun ’23US$38.91
US$74.00
+90.2%
33.5%US$114.00US$46.00US$18.234
May ’23US$38.66
US$74.00
+91.4%
33.5%US$114.00US$46.00US$22.994

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.